Core E: DIABETES TRANSLATIONAL RESEARCH CORE

核心 E：糖尿病转化研究核心

• 批准号: 8446559
• 负责人: WILLIAM V TAMBORLANE
• 金额: $ 20.45万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8446559
• 关键词: Adult; Advertising; Applications Grants; Area; Beta Cell; Biometry; Biopsy; Child; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communities; Complex; Computerized Medical Record; Core Facility; Data Analyses; Databases; Development; Diabetes Mellitus; Environment; Equipment; Functional Magnetic Resonance Imaging; Funding; Goals; Grant; Hospitals; Human; Human Resources; Image; Immune; Indirect Calorimetry; Infusion procedures; Institution; Institutional Review Boards; Instruction; Insulin; Laboratories; Magnetic Resonance; Magnetic Resonance Spectroscopy; Medical center; Metabolic; Metabolic Diseases; Mission; Muscle; Nursing Research; Nursing Staff; Participant; Peer Review; Performance; Positron-Emission Tomography; Productivity; Protocols documentation; Pump; Registries; Research; Research Design; Research Infrastructure; Research Personnel; Research Support; Research Technics; Resources; Scientist; Speed; System; Techniques; Technology; Therapeutic; Time; Training; Training and Education; Translational Research; Translations; Ursidae Family; base; bench to bedside; catalyst; cellular imaging; glucose and insulin clamps; improved; innovation; instrument; interdisciplinary collaboration; interest; medical schools; metabolic abnormality assessment; next generation; programs; protocol development; research facility; stable isotope

For many years, Yale has been one ofthe premier institutions in the world for clinical and translational research in diabetes. Our tradition of a cutting edge, broadly based clinical research program has been expanded in recent years to include areas such as, closed loop pumps, functional MRI, MR Spectroscopy and PET studies, beta cell imaging, and new immune-therapeutics forHD. The expansion of our translational research portfolio was made possible by the enhanced infrastructure provided by the Diabetes Translational Core (DTRC). The primary objectives of the DTRC are: 1. To provide specialized clinical and translational research infrastructure (trained personnel, access to equipment, laboratory resources, research facilities) to carry out complex metabolic, imaging, and immunological studies in diabetes; 2. To provide training in the conduct of a wide variety of metabolic research techniques (insulin-glucose clamps, with and without magnetic resonance spectroscopy and functional magnetic resonance imaging studies, stable isotope infusions, indirect calorimetry, muscle biopsies, closed-loop insulin delivery, etc.) for new investigators and research nursing staff; 3.To assist with grant and IRB protocol development via biostatistical support and in carrying out studies by assisting with the recruitment of study participants. A secondary aim of the DTRC is to coordinate and facilitate access of DRC investigators to the expanded translational research resources that are provided by the CTSA-supported Yale Center for Clinical Investigation (YCCI). During the next grant period, the DTRC will: 1. Provide research nursing support for studies of DTRC investigators on the Hospital Research Unit, Magnetic Resonance Research Center and the PET Center; 2. Establish a Diabetes Biostatistics Team, led by Dr. Dziura (an established investigator in diabetes in his own right) that will include support for data analysis by a Master's level Biostatistician; 3. Expand support that is provided to investigators for subject recruitment by integrating the Yale Diabetes Center Registry that was developed during the current grant period with the on-line recruitment instruments, local community engagement efforts and the research participation advertising campaign of YCCI for diabetes/metabolism studies. DTRC Investigators will also benefit from enhancements in informational technology infrastructure at Yale that include establishment of a single, medical center-wide electronic medical record; implementation of OnCore;, a clinical research management system and the establishment of a clinical research data repository.

多年来，耶鲁大学一直是世界上糖尿病临床和转化研究的主要机构之一。近年来，我们的尖端传统，广泛的临床研究计划已经扩展到包括闭环泵，功能性MRI，MR光谱和PET研究，β细胞成像和新的HD免疫疗法等领域。我们的转化研究组合的扩大是由糖尿病提供的增强基础设施成为可能 翻译核心（DTRC）。DTRC的主要目标是：1。提供专门的临床和转化研究基础设施（训练有素的人员，获得设备，实验室资源，研究设施），以进行糖尿病的复杂代谢，成像和免疫学研究; 2.提供各种代谢研究技术（胰岛素-葡萄糖钳夹， 没有磁共振波谱和功能性磁共振成像研究、稳定同位素输注、间接量热法、肌肉活检、闭环胰岛素递送等）为新的研究者和研究护理人员; 3.通过生物统计学支持协助赠款和IRB方案的制定，并通过协助招募研究参与者来开展研究。DTRC的第二个目的是协调和促进DRC研究人员访问CTSA支持的耶鲁临床研究中心（YCCI）提供的扩展翻译研究资源。在下一个资助期内，研究中心将：1.提供研究护理支持， DTRC研究者对医院研究单位、磁共振研究中心和PET中心的研究; 2.建立一个糖尿病生物统计学团队，由Dziura博士（他自己是一位成熟的糖尿病研究者）领导，包括由硕士水平的生物统计学家支持数据分析; 3.通过整合Yale Diabetes，扩大为研究者招募受试者提供的支持 中心注册表是在当前资助期内开发的，包括在线招募工具、当地社区参与工作和YCCI糖尿病/代谢研究的研究参与广告活动。DTRC研究人员还将受益于耶鲁大学信息技术基础设施的增强，包括建立单一的医疗中心范围内的电子病历;实施OnCore;临床研究管理系统和建立 临床研究数据库。